Patheon France
Patheon France is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study
Sponsor Intrabio Limited
- Start (EU)
- Latest update
- Estimated end
Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Phase III, randomized, placebo-controlled, double-blind, crossover study
Sponsor Intrabio Limited
- Start (EU)
- Latest update
- Estimated end
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low residual β-cell function at baseline.
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
An Exploratory, Multicenter, Randomized, double-blind, placebo-controlled study evaluating the effect and safety of pitolisant in children and adolescents with Autism Spectrum Disorders.
Sponsor Bioprojet Pharma
- Start (EU)
- Latest update
- Estimated end
Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory Distress Syndrome (RESPIRATIO)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Patheon France?
The 2026-10-09 snapshot links Patheon France to 5 distinct CTIS trials. Recorded services include Medicinal product management, Alternative DP (and placebo) batch manufacture, stability study, and quality control testing site, Bulk manufacture, QC and batch release (IMP and Placebo), Manufacture, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Patheon France?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Neurology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Patheon France conducted?
The linked trials record locations in 9 countries, including Germany, Italy, Spain, Austria, Belgium. These are trial locations, not confirmed office locations or countries where Patheon France delivered services.
What can this page tell me about Patheon France's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Patheon France. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Patheon France